Takara BioFRA:TF2 71 Interest Coverage is 1.04 as of Mar. 2026, which is 100% below its 10-year median of 856.08. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, Takara Bio ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Takara Bio's
Operating Income
for the
three
months ended in Mar. 2026 was €0.9 Mil. Takara Bio's Interest Expense for the
three
months ended in Mar. 2026 was €-0.9 Mil.
Takara Bio's interest coverage for the quarter that ended in Mar. 2026 was 1.04.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Takara Bio's Interest Coverage or its related term are showing as below:
FRA:TF2's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Takara Bio (FRA:TF2) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Takara Bio Interest Coverage Related Terms
Takara Bio Interest Coverage Historical Data
* Premium members only.
The historical data trend for Takara Bio's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:TF2 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Takara Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Takara Bio's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Interest Coverage of 1.04 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Takara Bio and its competitors. This is 100% below median its historical median of 856.08. According to the industry distribution chart, Takara Bio ranks #999999 out of 377 companies in the Biotechnology industry.
Is Takara Bio's Interest Coverage too high?
Takara Bio's current Interest Coverage of 1.04 is 100% below median its 10-year median of 856.08. The Biotechnology industry median Interest Coverage is 106.07. Takara Bio's value of 1.04 is 99% below this industry median. Based on the distribution chart, Takara Bio ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #999999 out of 377 companies for Interest Coverage. This places Takara Bio in the lower half of its industry. The industry median Interest Coverage is 106.07. Takara Bio's value of 1.04 is 99% below this benchmark. While the company's 10-year median is 856.08 vs. the industry median of 106.07, Takara Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Interest Coverage of 1.04 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Interest Coverage is 1.04, which is 100% below median its own 10-year median of 856.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Interest Coverage is 1.04, which is 100% below median its 10-year median of 856.08 and 99% below the Biotechnology industry median of 106.07. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Interest Coverage is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Interest Coverage: 1.04 (100% below median its 10-year median of 856.08)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
Industry Position: 99% below the Biotechnology median (#999999 of 377)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
